MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Epigenetic silencing of the MGMT (O6-methylguanine-DNA methyltransferase) DNA-repair gene by promoter methylation compromises DNA repair and has been associated with longer survival in patients with glioblastoma who receive alkylating agents. METHODS: We tested the relationship between MGMT silencing in the tumor and the survival of patients who were enrolled in a randomized trial comparing radiotherapy alone with radiotherapy combined with concomitant and adjuvant treatment with temozolomide. The methylation status of the MGMT promoter was determined by methylation-specific polymerase-chain-reaction analysis. RESULTS: The MGMT promoter was methylated in 45 percent of 206 assessable cases. Irrespective of treatment, MGMT promoter methylation was an independent favorable prognostic factor (P<0.001 by the log-rank test; hazard ratio, 0.45; 95 percent confidence interval, 0.32 to 0.61). Among patients whose tumor contained a methylated MGMT promoter, a survival benefit was observed in patients treated with temozolomide and radiotherapy; their median survival was 21.7 months (95 percent confidence interval, 17.4 to 30.4), as compared with 15.3 months (95 percent confidence interval, 13.0 to 20.9) among those who were assigned to only radiotherapy (P=0.007 by the log-rank test). In the absence of methylation of the MGMT promoter, there was a smaller and statistically insignificant difference in survival between the treatment groups. CONCLUSIONS: Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Intriguingly, PT2385 treatment of the same PDX cell line in vitro showed no impact on cell viability or proliferation, suggesting that the survival advantage mediated by PT2385 may be linked to inhibition of tumor aspects required for in vivo progression.”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [55]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Indeed, selective HIF-2α inhibition using PT2385 increased animal survival in an orthotropic GBM PDX model although no significant differences in tumor size (detected by bioluminescent imaging) was observed [55].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [55]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationGene Silencing in Cancer in Association with Promoter Hypermethylation
Herman, J. G., & Baylin, S. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023075 · Cited by 3,422
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., & Herman, J. G. (1999) · PubMed · Cited by 1,253
Predicting lung cancer by detecting aberrant promoter methylation in sputum.
Palmisano, W. A., Divine, K. K., Saccomanno, G., Gilliland, F. D., Baylin, S. B., Herman, J. G., & Belinsky, S. A. (2000) · PubMed · Cited by 891
MGMT: its role in cancer aetiology and cancer therapeutics
Gerson, S. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1319 · Cited by 813
Hegi, M. E., Diserens, A.-C., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., Van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 783
Self-citationFriedman, H. S., McLendon, R. E., Kerby, T., Dugan, M., Bigner, S. H., Henry, A. J., Ashley, D. M., Krischer, J., Lovell, S., Rasheed, K., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3851 · Cited by 423
Jaeckle, K. A., Eyre, H. J., Townsend, J. J., Schulman, S., Knudson, H. M., Belanich, M., Yarosh, D. B., Bearman, S. I., Giroux, D. J., & Schold, S. C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3310 · Cited by 297
Ochs, K., & Kaina, B. (2000) · PubMed · Cited by 291
Research works printed but not linked: 8
- Ochs K, 2000, Cancer Res, 60, 5815
- Liu L, 1996, Cancer Res, 56, 5375
- Belanich M, 1996, Cancer Res, 56, 783
- Silber JR, 1999, Clin Cancer Res, 5, 807
- Qian XC, 1997, Cancer Res, 57, 3672
- Esteller M, 1999, Cancer Res, 59, 793
- Palmisano WA, 2000, Cancer Res, 60, 5954
- Quinn JA, 2003, Prog Proc Am Soc Clin Oncol, 22, 103
Cited by
Items 301–330 of 330
Morano, F., Raimondi, A., Pagani, F., Lonardi, S., Salvatore, L., Cremolini, C., Murgioni, S., Randon, G., Palermo, F., Antonuzzo, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02583 · Cited by 134
“Temozolomide is an oral alkylating agent approved for patients with glioblastoma (GBM) and its efficacy in this disease is related to a validated predictive biomarker, ie, O(6)-methylguanine–DNA methyltransferase (MGMT) promotermethylation.(8) SinceMGMT is a key enzyme involved in the repair of DNA damage induced by a…”
BackgroundEllingson, B. M. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0506-0 · Cited by 132
Yoshimoto, K., Mizoguchi, M., Hata, N., Murata, H., Hatae, R., Amano, T., Nakamizo, A., & Sasaki, T. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00186 · Cited by 126
Beier, C. P., Schmid, C., Gorlia, T., Kleinletzenberger, C., Beier, D., Grauer, O., Steinbrecher, A., Hirschmann, B., Brawanski, A., Dietmaier, C., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-308 · Cited by 125
Self-citationWiewrodt, D., Nagel, G., Dreimüller, N., Hundsberger, T., Perneczky, A., & Kaina, B. (2008) · International Journal of Cancer · doi:10.1002/ijc.23219 · Cited by 114
“methylation has been suggested to be a predictive factor in gliomblastoma therapy.(18,19,46) Whether MGMT promoter hypermethyl-”
BackgroundInfluentialBiological activity of tumor-treating fields in preclinical glioma models
Silginer, M., Weller, M., Stupp, R., & Roth, P. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.171 · Cited by 111
Self-citationLiang, W.-W., Lu, R. J.-H., Jayasinghe, R. G., Foltz, S. M., Porta-Pardo, E., Geffen, Y., Wendl, M. C., Lazcano, R., Kolodziejczak, I., Song, Y., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.013 · Cited by 105
Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy
Yi, Y., Hsieh, I.-Y., Huang, X., Li, J., & Zhao, W. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00477 · Cited by 105
A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells
Kaltschmidt, C., Banz-Jansen, C., Benhidjeb, T., Beshay, M., Förster, C., Greiner, J., Hamelmann, E., Jorch, N., Mertzlufft, F., Pfitzenmaier, J., et al. (2019) · Cancers · doi:10.3390/cancers11050655 · Cited by 102
“Of note, MGMT promoter hypermethylation has proven an important predictive biomarker for benefit from alkylating chemotherapy as well as powerful prognostic factor [59,60].”
BackgroundMaertens, O., Kuzmickas, R., Manchester, H. E., Emerson, C. E., Gavin, A. G., Guild, C. J., Wong, T. C., De Raedt, T., Bowman-Colin, C., Hatchi, E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0879 · Cited by 95
“Fortunately, however, this defect consistently segregates with MGMT expression, which has already proven to be a tractable clinical biomarker in other settings (25, 26).”
BackgroundA GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas
Agnihotri, S., Wolf, A., Munoz, D. M., Smith, C. J., Gajadhar, A., Restrepo, A., Clarke, I. D., Fuller, G. N., Kesari, S., Dirks, P. B., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20102099 · Cited by 92
“We next used established and primary GBM cell lines (Sarkaria et al., 2006) to evaluate whether the GATA4mediated sensitization was dependent on TP53 status and MGMT, the DNA repair enzyme which is most often implicated in temozolomide resistance (Hegi et al., 2004, 2005).”
Chaichana, K. L., Pinheiro, L., & Brem, H. (2015) · Therapeutic Delivery · doi:10.4155/tde.14.114 · Cited by 91
Peng, T., Ma, X., Hua, W., Wang, C., Chu, Y., Sun, M., Fermi, V., Hamelmann, S., Lindner, K., Shao, C., et al. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.01.002 · Cited by 86
Reardon, D. A., & Cheresh, D. (2011) · Genes & Cancer · doi:10.1177/1947601912450586 · Cited by 76
“Of note, 45 patients (87%) in this study had tumor material available for analysis of the DNA repair protein MGMT, which is upregulated based on the lack of promoter methylation in approximately 60% of newly diagnosed GBM patients.(51) MGMT promoter methylation was detected in 23 (51%) of these patients.”
BackgroundBerberich, A., Kessler, T., Thomé, C. M., Pusch, S., Hielscher, T., Sahm, F., Oezen, I., Schmitt, L.-M., Ciprut, S., Hucke, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1580 · Cited by 75
“However, today’s guidelines still advocate the use of temozolomide regardless of MGMT status and alternatives for patients not likely benefitting from temozolomide are yet to be developed (14-16).”
BackgroundOverview of prognostic factors in adult gliomas
Sharma, A., & Graber, J. J. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-640 · Cited by 70
“Notably, the benefits of the chemotherapy was most notable in the patient who had a methylation in the MGMT promoter gene in their tumors (31).”
BackgroundFate mapping of neural stem cell niches reveals distinct origins of human cortical astrocytes
Allen, D. E., Donohue, K. C., Cadwell, C. R., Shin, D., Keefe, M. G., Sohal, V. S., & Nowakowski, T. J. (2022) · Science · doi:10.1126/science.abm5224 · Cited by 67
Jansen, R. W., van Amstel, P., Martens, R. M., Kooi, I. E., Wesseling, P., de Langen, A. J., Menke-Van der Houven van Oordt, C. W., Jansen, B. H. E., Moll, A. C., Dorsman, J. C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24893 · Cited by 63
“MGMT-methylated glioblastoma respond better to DNA alkylating chemotherapy with improved prognosis [41, 42].”
BackgroundTreatment considerations for MGMT-unmethylated glioblastoma
Taylor, J. W., & Schiff, D. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0507-z · Cited by 60
Renfrow, J. J., Soike, M. H., West, J. L., Ramkissoon, S. H., Metheny-Barlow, L., Mott, R. T., Kittel, C. A., D’Agostino, R. B., Tatter, S. B., Laxton, A. W., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72290-2 · Cited by 45
Identification of responders to immune checkpoint therapy: Which biomarkers have the highest value?
Liebl, M. C., & Hofmann, T. G. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15992 · Cited by 58
Artificial intelligence in glioma imaging: Challenges and advances
Jin, W., Fatehi, M., Abhishek, K., Mallya, M., Toyota, B., & Hamarneh, G. (2020) · Journal of Neural Engineering · doi:10.1088/1741-2552/ab8131 · Cited by 55
“Moreover, the greatest benefits from TMZ are seen in patients with methylguanine methyl transferase (MGMT) promoter methylation [11, 12].”
BackgroundAutophagy Regulation on Cancer Stem Cell Maintenance, Metastasis, and Therapy Resistance
Wang, X., Lee, J., & Xie, C. (2022) · Cancers · doi:10.3390/cancers14020381 · Cited by 53
“Thus, the hypermethylation cannot be removed, which induces DNA damage and triggers apoptosis [82,83].”
BackgroundBernstock, J. D., Ye, D., Gessler, F. A., Lee, Y.-J., Peruzzotti-Jametti, L., Baumgarten, P., Johnson, K. R., Maric, D., Yang, W., Kögel, D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07631-9 · Cited by 46
Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches
Gilbert, M. R. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.09.008 · Cited by 45
An epigenetic mechanism for capecitabine resistance in mesothelioma
Kosuri, K. V., Wu, X., Wang, L., Villalona-Calero, M. A., & Otterson, G. A. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.095 · Cited by 44
Targeted Therapies for Malignant Glioma: Progress and Potential
Mercer, R. W., Tyler, M. A., Ulasov, I. V., & Lesniak, M. S. (2009) · BioDrugs · doi:10.2165/00063030-200923010-00003 · Cited by 39
Caregiver burden by treatment and clinical characteristics of patients with glioblastoma
Au, T. H., Willis, C., Reblin, M., Peters, K. B., Nghiemphu, P. L., Taylor, J. W., Colman, H., Cohen, A. L., Ormond, D. R., Chakravarti, A., et al. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-021-06514-0 · Cited by 34
In vitro anti‐tubulin effects of mebendazole and fenbendazole on canine glioma cells
Lai, S. R., Castello, S. A., Robinson, A. C., & Koehler, J. W. (2017) · Veterinary and Comparative Oncology · doi:10.1111/vco.12288 · Cited by 31
Schaff, L. R., & Lassman, A. B. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.02.008 · Cited by 13
Metadata
- Authors
- Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., Bromberg, J. E. C., Hau, P., Mirimanoff, R. O., Cairncross, J. G., Janzer, R. C., & Stupp, R.
- Affiliations
- Centre Hospitalier Universitaire Vaudois (CH)
- European Organisation for Research and Treatment of Cancer (NL)
- University of Tübingen (DE)
- Erasmus MC (NL)
- Medical University of Vienna (AT)
- Princess Margaret Cancer Centre (CA)
- University Hospital of Bern (CH)
- University Medical Center Utrecht (NL)
- University of Regensburg (DE)
- University of Calgary (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-10
- Volume
- 352
- Issue
- 10
- Pages
- 997-1003
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2105100844
- Cited by
- 7,405
- References
- 22
- Citations by year
- 2026: 344 · 2025: 342 · 2024: 383 · 2023: 407 · 2022: 444 · 2021: 525 · 2020: 442 · 2019: 391 · 2018: 361 · 2017: 390 · 2016: 391 · 2015: 391 · 2014: 360 · 2013: 369 · 2012: 372
- FWCI
- 84.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- glioblastoma, MGMT promoter methylation, O6-methylguanine-DNA methyltransferase, temozolomide, epigenetic silencing, DNA repair, alkylating agents, radiotherapy, survival benefit, prognostic factors
- MeSH terms
- Temozolomide, Brain Neoplasms, Dacarbazine, Glioblastoma, Humans, Promoter Regions, Genetic, Survival Analysis, Randomized Controlled Trials as Topic, Polymerase Chain Reaction, Chemotherapy, Adjuvant, Disease-Free Survival, Antineoplastic Agents, Alkylating, DNA Methylation, O(6)-Methylguanine-DNA Methyltransferase, Gene Silencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.